Paradigm Biocapital Advisors LP - 30 Jun 2025 SCHEDULE 13G/A Report for Janux Therapeutics, Inc. Common Stock, $0.001 par value per share (JANX)

Filing Manager
Paradigm Biocapital Advisors LP
Reporting Manager
Paradigm BioCapital Advisors LP
Security
Janux Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
JANX
Shares outstanding
59,597,102 shares
Disclosed Ownership
2,920,258 shares
Ownership
4.9%
Form type
SCHEDULE 13G/A
Filing time
14 Aug 2025, 16:31:25 UTC
Date of event
30 Jun 2025
Previous filing
14 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Paradigm Biocapital Advisors LP disclosed 4.9% ownership in Janux Therapeutics, Inc. Common Stock, $0.001 par value per share (JANX) on 30 Jun 2025."

Quick Takeaways

  • Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for Janux Therapeutics, Inc. Common Stock, $0.001 par value per share (JANX).
  • Disclosed ownership: 4.9%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 14 Feb 2025.
  • Current filing was accepted on 14 Aug 2025, 16:31.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Paradigm BioCapital Advisors LP 4.9% 2,920,258 2,920,258 0 /s/ David K. Kim David K. Kim / Authorized Signatory
Paradigm BioCapital Advisors GP LLC 4.9% 2,920,258 2,920,258 0 /s/ David K. Kim David K. Kim / Authorized Signatory
Senai Asefaw, M.D. 4.9% 2,920,258 2,920,258 0 /s/ Senai Asefaw, M.D. N/A
Paradigm BioCapital International Fund Ltd. 4.4% 2,593,376 2,593,376 0 /s/ David K. Kim David K. Kim / Authorized Signatory

Sponsored